Natera, Inc. (NTRA:NASDAQ) closed at $403.95 on October 23, 2026, up 0.64% on the day. The stock trades 7.6% below its 52-week high of $437.41 and 123.2% above its 52-week low of $181.00. Over the past year, it gained 109.8%. Natera, Inc. is part of the Health Care sector (Medical Specialities).
In 252 trading sessions since October 23, 2025, NTRA closed higher on 135 days (54%). Its best day was August 7, 2026 (+21.37%) and its worst was May 8, 2026 (-11.64%). The stock moved 10% or more in a single session 3 times. It opened at least 5% above the previous day's high 1 time.
Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direc...
Find more stocks like NTRA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.